BR112013017154A2 - uso de fitocanabinóide canabidiol (cbd) em combinação com um fármaco antiepiléptico padrão (saed) no tratamento de epilepsia - Google Patents

uso de fitocanabinóide canabidiol (cbd) em combinação com um fármaco antiepiléptico padrão (saed) no tratamento de epilepsia

Info

Publication number
BR112013017154A2
BR112013017154A2 BR112013017154A BR112013017154A BR112013017154A2 BR 112013017154 A2 BR112013017154 A2 BR 112013017154A2 BR 112013017154 A BR112013017154 A BR 112013017154A BR 112013017154 A BR112013017154 A BR 112013017154A BR 112013017154 A2 BR112013017154 A2 BR 112013017154A2
Authority
BR
Brazil
Prior art keywords
saed
cbd
epilepsy
treatment
combination
Prior art date
Application number
BR112013017154A
Other languages
English (en)
Other versions
BR112013017154A8 (pt
Inventor
Benjamin Whalley
Claire Williams
Gary Stephens
Original Assignee
Gw Pharma Ltd
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43639013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013017154(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gw Pharma Ltd, Otsuka Pharma Co Ltd filed Critical Gw Pharma Ltd
Publication of BR112013017154A2 publication Critical patent/BR112013017154A2/pt
Publication of BR112013017154A8 publication Critical patent/BR112013017154A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

uso de fitocanabinóide canabidiol (cbd) em combinação com um fármaco antiepiléptico padrão (saed) no tratamento de epilepsia a invenção relaciona-se com a utilização de canabidiol (cbd), a uma dose maior do que 300mg/dia, em combinação com um fármaco antiepiléptico padrão (saed) , que atua através de canais de sódio ou cálcio, para utilização no tratamento de epilepsia. o saed, de preferência, modifica as correntes de cálcio neuronais de baixo limiar ou transitórias, ou •reduz disparo neuronal de alta frequência e potenciais de ação dependentes de sódio e aumenta os efeitos do gaba. saeds preferidos são etossuximida e valproato.
BR112013017154A 2011-01-04 2012-01-03 Uso de fitocanabinóide canabidiol (cbd) em combinação com um fármaco antiepiléptico padrão (saed) no tratamento de epilepsia BR112013017154A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1100043.7A GB2487712B (en) 2011-01-04 2011-01-04 Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
PCT/GB2012/050002 WO2012093255A1 (en) 2011-01-04 2012-01-03 Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy

Publications (2)

Publication Number Publication Date
BR112013017154A2 true BR112013017154A2 (pt) 2016-09-20
BR112013017154A8 BR112013017154A8 (pt) 2018-04-03

Family

ID=43639013

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013017154A BR112013017154A8 (pt) 2011-01-04 2012-01-03 Uso de fitocanabinóide canabidiol (cbd) em combinação com um fármaco antiepiléptico padrão (saed) no tratamento de epilepsia

Country Status (20)

Country Link
US (2) US20140155456A9 (pt)
EP (2) EP2661263B1 (pt)
JP (1) JP6076259B2 (pt)
KR (1) KR101853634B1 (pt)
CN (2) CN103391775A (pt)
AR (1) AR084559A1 (pt)
AU (1) AU2012204800C1 (pt)
BR (1) BR112013017154A8 (pt)
CA (1) CA2822907C (pt)
CO (1) CO6731122A2 (pt)
DK (1) DK2661263T3 (pt)
ES (1) ES2877502T3 (pt)
GB (1) GB2487712B (pt)
IL (1) IL227298A (pt)
MX (1) MX349027B (pt)
RU (1) RU2013136378A (pt)
SG (1) SG191835A1 (pt)
TW (1) TWI532479B (pt)
WO (1) WO2012093255A1 (pt)
ZA (1) ZA201305508B (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9168278B2 (en) * 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US9820988B2 (en) * 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
WO2016044370A1 (en) 2014-09-16 2016-03-24 India Globalization Capital, Inc. Cannabinoid composition and method for treating pain
GB2531278A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531281A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US10751300B2 (en) 2015-01-25 2020-08-25 India Globalization Capital, Inc. Composition and method for treating seizure disorders
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) * 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
JP6893213B2 (ja) 2015-12-22 2021-06-23 ゾゲニクス インターナショナル リミテッド フェンフルラミン組成物およびその調製法
GB2548873B (en) * 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
WO2017218629A1 (en) * 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders
AU2017290107A1 (en) 2016-06-29 2019-01-17 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
RU2746000C2 (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
CN108236608B (zh) * 2016-12-27 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与氨己烯酸的药物组合物及其用途
CN108245499B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与双链脂肪酸类抗癫痫药物的组合物及其用途
CN108245510B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与乙丙酰脲类抗癫痫药物的组合物及其用途
CN108245517B (zh) * 2016-12-29 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与拉莫三嗪的药物组合物及其用途
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB2572737A (en) * 2018-01-24 2019-10-16 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
US11571397B2 (en) 2018-05-11 2023-02-07 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2019241005A1 (en) 2018-06-14 2019-12-19 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
GB2580881A (en) 2018-11-30 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2581517A (en) 2019-02-22 2020-08-26 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2583526A (en) 2019-05-03 2020-11-04 Gw Res Ltd Use of cannabidiol in the treatment of tuberous sclerosis complex
CN110101804A (zh) * 2019-05-30 2019-08-09 厦门梓素生物科技有限公司 一种含大麻二酚提取物的癫痫药物组合及其制备方法
JP2022547922A (ja) * 2019-09-17 2022-11-16 ジナーバ・ファーマシューティカルズ・インコーポレイテッド Ｓｙｎｇａｐ１脳症の治療
GB2588460A (en) * 2019-10-25 2021-04-28 Gw Res Ltd Use of cannabidiol preparations in the treatment of temporal lobe epilepsy
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
CN113521050B (zh) * 2020-04-20 2023-05-09 铸鼎(北京)医学技术发展有限公司 含有大麻二酚的组合物及其在治疗全身炎症反应综合征中的用途
EP3912485A1 (en) 2020-05-18 2021-11-24 Del-Vis Sp. z o.o. Cigarette product and a method for manufacturing the product
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
GB2597296A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
GB2604132A (en) 2021-02-25 2022-08-31 Gw Res Ltd Use of cannabidiol and clobazam in the treatment of childhood-onset epilepsy syndromes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1140635B (de) 1959-10-24 1962-12-06 Ellenberger & Poensgen Mehrpoliger Motorschutzschalter
SE9802331L (sv) * 1998-06-29 1999-12-30 Ericsson Telefon Ab L M Metod och arrangemang avseende service vid ett intelligent nät
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
DE10296335T5 (de) 2001-02-14 2004-04-15 G W Pharma Ltd., Salisbury Pharmazeutische Formulierungen
GB2381450B (en) * 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
GB2450753B (en) 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2471523A (en) * 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy

Also Published As

Publication number Publication date
WO2012093255A1 (en) 2012-07-12
GB2487712A8 (en) 2012-12-26
EP3791868A1 (en) 2021-03-17
AU2012204800C1 (en) 2020-02-27
GB2487712B (en) 2015-10-28
GB2487712A (en) 2012-08-08
CN107510846A (zh) 2017-12-26
BR112013017154A8 (pt) 2018-04-03
EP2661263B1 (en) 2021-04-14
AU2012204800B2 (en) 2017-05-25
IL227298A (en) 2017-11-30
US20220395470A1 (en) 2022-12-15
RU2013136378A (ru) 2015-02-10
JP2014501271A (ja) 2014-01-20
MX2013007609A (es) 2014-03-21
TWI532479B (zh) 2016-05-11
ES2877502T8 (es) 2022-01-28
NZ709911A (en) 2016-12-23
KR20130132972A (ko) 2013-12-05
ZA201305508B (en) 2014-04-30
CA2822907A1 (en) 2012-07-12
TW201306826A (zh) 2013-02-16
KR101853634B1 (ko) 2018-05-02
SG191835A1 (en) 2013-08-30
IL227298A0 (en) 2013-09-30
US20140155456A9 (en) 2014-06-05
GB201100043D0 (en) 2011-02-16
CO6731122A2 (es) 2013-08-15
MX349027B (es) 2017-07-07
US20130296398A1 (en) 2013-11-07
NZ613307A (en) 2015-11-27
DK2661263T3 (da) 2021-07-05
CA2822907C (en) 2020-08-18
AR084559A1 (es) 2013-05-22
CN103391775A (zh) 2013-11-13
JP6076259B2 (ja) 2017-02-08
EP2661263A1 (en) 2013-11-13
ES2877502T3 (es) 2021-11-17

Similar Documents

Publication Publication Date Title
BR112013017154A2 (pt) uso de fitocanabinóide canabidiol (cbd) em combinação com um fármaco antiepiléptico padrão (saed) no tratamento de epilepsia
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
CO2017009008A2 (es) Oligómeros antisentido de tau
BR112015013105A2 (pt) composições de irna de pcsk9 e métodos de uso das mesmas
MX2014002668A (es) Tratamiento de enfermedades relacionadas con subunidades alfa de canales de sonido regulados por voltaje (scnxa) con moleculas pequeñas.
GT201700246A (es) Métodos y kits para tratar la depresión
BR112015032432A2 (pt) Conjugado de oligonucleotídeo antisense, oligômero, composição farmacêutica, uso de um oligômero ou conjugado de oligonucleotídeo antisense ou composição farmacêutica, método de tratamento da hipercolesterolemia ou de distúrbios relacionados e método in vivo ou in vitro
EA201890571A1 (ru) Способы и композиции для лечения нарушения, ассоциированного с геном пропротеинконвертазы субтилизин/кексинового типа (pcsk9)
EA201590590A1 (ru) Модуляторы рецептора андрогенов и их применение
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
BR112012031163A2 (pt) métodos de terapia combinada para tratamento de doenças proliferativas
CO6761400A2 (es) Combinación de análogos de glucagón acilados con análogos de insulina
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
EA202091999A3 (ru) Применение ингибиторов dpp iv
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
EA201290975A1 (ru) Применение фитоканнабиноида каннабидиварина (cbdv) для лечения эпилепсии
BR112016029713A2 (pt) métodos para o tratamento de sobrepeso ou obesidade
EA201890454A1 (ru) Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств
CO6761363A2 (es) Masa de chocolate
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
BR112015022538A2 (pt) terapia de indução de rituximab seguida por terapia de acetato de glatirâmero
EA201492067A1 (ru) Применение связывающих семафорин-4d молекул для промотирования нейрогенеза после инсульта
BR112016020381A8 (pt) sistemas e métodos para liberação de drogas para tratamento do câncer de bexiga com gencitabina.
BR112019003731A2 (pt) aplicação de pridopidina para tratamento de distonias

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: GW PHARMA LIMITED (GB) , OTSUKA PHARMACEUTICAL CO LIMITED (JP)

Owner name: GW PHARMA LIMITED (GB) , OTSUKA PHARMACEUTICAL CO

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: GW PHARMA LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: GW PHARMA LIMITED (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL